(Q46084625)

19 December 2017

title

Intravitreal bevacizumab (Avastin) for the treatment of cystoid macular edema in Behçet disease (English)

1 reference

19 December 2017

0 references

1 reference

cystoid macular edema

1 reference

Ahmad Mirshahi

1

1 reference

19 December 2017

Abed Namavari

2

1 reference

19 December 2017

Ali Djalilian

3

1 reference

19 December 2017

Yashar Moharamzad

4

1 reference

19 December 2017

Hormoz Chams

5

1 reference

19 December 2017

language of work or name

1 reference

1 January 2009

1 reference

19 December 2017

Ocular Immunology and Inflammation

published in

1 reference

19 December 2017

volume

17

1 reference

19 December 2017

issue

1

1 reference

19 December 2017

page(s)

59-64

1 reference

19 December 2017

Clinical features of chinese patients with Behçet's disease

cites work

1 reference

https://api.crossref.org/works/10.1080%2F09273940802553295

Cystoid macular edema in uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940802553295

Causes and frequency of blindness in patients with intraocular inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940802553295

Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behçet's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940802553295

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940802553295

BEHCET'S DISEASE; A REPORT OF 28 CASES.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940802553295

Macular grid laser photocoagulation in uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940802553295

Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940802553295

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940802553295

Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940802553295

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940802553295

Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940802553295

Targeted pharmacotherapy of retinal diseases with ranibizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940802553295

Medical treatment of cystoid macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940802553295

Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940802553295

Intraocular pressure after intravitreal injection of triamcinolone acetonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940802553295

Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940802553295

Inhibitors of ocular neovascularization: promises and potential problems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273940802553295

10.1080/09273940802553295

21 January 2018

Identifiers

DOI

1 reference

19 December 2017

PubMed ID

19294576

1 reference

19 December 2017